You are here: Industry Insights > GSK

News List

Nexelis Acquires GSK Vax Lab in Marburg contractpharma
January 21, 2021
Nexelis has signed an asset purchase agreement with GlaxoSmithKline to acquire its GCLP-certified clinical bioanalytical lab in Marburg, Germany.  
NICE backs GSK’s Zejula in advanced ovarian cancer pharmatimes
January 18, 2021
The UK’s National Institute for Health and Care Excellence (NICE) has recommended the use of GlaxoSmithKline’s Zejula (niraparib) on the NHS for women with newly diagnosed advanced ovarian cancer.
GSK, MMV filing for Kozenis in paediatric populations with P. vivax malaria accepted by Australian TGA pharmaceutical-business-review
January 14, 2021
GSK and Medicines for Malaria Venture (MMV) announced today that the Australian Therapeutic Goods Administration (TGA) accepted the submission of a Category 1 application to extend the indication of single-dose Kozenis (tafenoquine) to paediatric ...
GSK, Vir Biotechnology to evaluate neutralising Covid-19 antibody in AGILE study pharmaceutical-business-review
January 14, 2021
GlaxoSmithKline, along with Vir Biotechnology, has agreed with the UK-based AGILE initiative to assess VIR-7832 in patients with mild to moderate Covid-19 in a phase 1b/2a clinical study.
Sosei Heptares and GSK sign collaboration and license pact targeting GI immune disorders expresspharma
December 22, 2020
Sosei Heptares to get an upfront payment, research funding and potential near-term development milestones of up to £34 million ($44 million), potential downstream payments of up to £336 million ($437 million) and tiered royalties.
GSK gets FDA nod for Benlysta to treat adult patients with active lupus nephritis pharmaceutical-business-review
December 21, 2020
GlaxoSmithKline (GSK) has secured approval from the US Food and Drug Administration (FDA) for its Benlysta (belimumab) to treat adult patients with active lupus nephritis (LN) who are securing standard therapy.
Vir Biotechnology and GSK announce start of NIH-sponsored ACTIV-3 trial evaluating VIR-7831 in hospitalised adults with COVID-19 worldpharmanews
December 21, 2020
Vir Biotechnology, Inc. and GlaxoSmithKline plc announced that the first patient has been dosed in a new sub-trial of the National Institutes of Health's (NIH) Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Program Phase 3 ...
GSK co-leads investment in ‘disease rebalancing’ Adrestia Therapeutics pharmatimes
December 21, 2020
GlaxoSmithKline, alongside Ahren Innovation Capital, will co-lead series A investment in UK-based biotech company Adrestia Therapeutics.
Sanofi and GSK postpone Covid-19 vaccine trial to optimise candidate pharmaceutical-technology
December 14, 2020
Sanofi and GlaxoSmithKline (GSK) have decided to delay their Covid-19 vaccine programme because their adjuvanted recombinant protein vaccine failed to produce a sufficient immune response in older adults enrolled in a US Phase I/II trial.
FDA set to review GSK’s Nucala for nasal polyps pharmatimes
December 11, 2020
The US Food and Drug Administration (FDA) is set to review GlaxoSmithKline’s (GSK) Nucala, after accepting a regulatory submission seeking approval for its use in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 40 41 Next page